August 23: The Week in Cancer News
Early immunotherapy may make more liver cancer patients eligible for surgery, and the FDA approves a new use for a lung cancer treatment.
Progress Against Cancer
Early immunotherapy may make more liver cancer patients eligible for surgery, and the FDA approves a new use for a lung cancer treatment.
The FDA approved lazertinib plus amivantamab-vmjw for the treatment of certain EGFR-mutated lung cancers. The U.S. Food and Drug Administration (FDA) has approved lazertinib (Lazcluze), in combination with amivantamab-vmjw (Rybrevant), for the first-line treatment...
Durvalumab can now be used with chemotherapy for certain patients with resectable non-small cell lung cancer. The U.S. Food and Drug Administration (FDA) has granted approval to the neoadjuvant combination of durvalumab (Imfinzi) and...
Immunotherapy may make surgery an option for patients who would be considered ineligible under traditional rules. Surgery is usually the best treatment for early-stage hepatocellular carcinoma, the most common type of liver cancer, but...
The FDA approved axatilimab-csfr, an inhibitor of monocytes and macrophages, for certain patients with chronic graft-versus-host disease. The U.S. Food and Drug Administration (FDA) has approved axatilimab-csfr (Niktimvo) for the treatment of adult and...
More endometrial cancer patients can now receive an immunotherapy, and taking aspirin regularly may help some people reduce their risk for colorectal cancer.
The FDA has approved vorasidenib to treat certain brain tumors harboring an IDH1 or IDH2 mutation. The U.S. Food and Drug Administration (FDA) has approved vorasidenib (Voranigo) for the treatment of adult and pediatric...
Blood test approval widens access to colorectal cancer screening option, and language barriers interrupt cancer care before it starts.
Afamitresgene autoleucel has received accelerated approval to treat certain patients with synovial sarcoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to afamitresgene autoleucel (Tecelra, afami-cel) for the treatment of certain...
The FDA has approved dostarlimab-gxly plus chemotherapy to treat more patients with endometrial cancer. The U.S. Food and Drug Administration (FDA) has approved dostarlimab-gxly (Jemperli) in combination with the chemotherapies carboplatin and paclitaxel, followed...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More